Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Grace Therapeutics ( (GRCE) ) has shared an update.
On September 12, 2025, Grace Therapeutics, Inc. held its Annual Meeting of Stockholders, with 57.32% of shares represented. Key outcomes included the election of directors, approval of executive compensation, and ratification of KPMG LLP as the independent auditor for the fiscal year ending March 31, 2026.
The most recent analyst rating on (GRCE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Grace Therapeutics stock, see the GRCE Stock Forecast page.
Spark’s Take on GRCE Stock
According to Spark, TipRanks’ AI Analyst, GRCE is a Neutral.
Grace Therapeutics is navigating a challenging financial landscape, marked by no revenue and persistent operational losses, which are somewhat mitigated by a strong equity base and absence of debt. The stock shows positive technical momentum but is at risk of being overbought. The negative P/E ratio highlights the risk associated with the company’s current financial performance and lack of earnings. Strategic management is required to improve operational viability and financial sustainability.
To see Spark’s full report on GRCE stock, click here.
More about Grace Therapeutics
Grace Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing therapeutic solutions. The company is involved in producing and marketing pharmaceutical products, with a market focus on innovative treatments.
Average Trading Volume: 79,342
Technical Sentiment Signal: Buy
Current Market Cap: $44.53M
See more insights into GRCE stock on TipRanks’ Stock Analysis page.